

■ HL-60 cells

Human HL-60 cells were isolated from the peripheral blood of a patient with Acute Promyelocytic Leukemia.

■ Tumour growth *in vivo*

Tumour fragments were surgically implanted in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing HL-60 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.




Figure 1: Tumour growth curve of the HL-60 cells as xenograft
Mean ± SEM (n=6; take rate 100%)

Antineo can also perform an IV implantation, using hCD45 Flow Cytometry as follow-up of tumour progression.

■ Standard-Of-Care Drug Responses

Daunorubicine 4 mg/kg / Aracytine 10 mg/kg, once per week → Response




Figure 2: Effect of Dauno/AraC treatment on HL-60 tumour growth
Mean ± SEM (n=6 per group; take rate 100%)